Claims
- 1. A pharmaceutical composition comprising N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or a pharmacologically acceptable salt thereof, and an HMG-CoA reductase inhibitor.
- 2. The pharmaceutical composition according to claim 1 wherein the HMG-CoA reductase inhibitor is Pravastatin, Lovastatin, Simvastatin, Fluvastatin, Rivastatin, Atorvastatin, Rosuvastatin or Pitavastatin.
- 3. The pharmaceutical composition according to claim 1 wherein the HMG-CoA reductase inhibitor is Pravastatin, Lovastatin, Simvastatin, Fluvastatin, Atorvastatin, Rosuvastatin or Pitavastatin.
- 4. The pharmaceutical composition according to claim 1 wherein the HMG-CoA reductase inhibitor is Pravastatin, Atorvastatin or Pitavastatin.
- 5. The pharmaceutical composition according to claim 1 wherein the HMG-CoA reductase inhibitor is Pitavastatin or Atorvastatin.
- 6. The pharmaceutical composition according to claim 1 wherein the HMG-CoA reductase inhibitor is Pravastatin.
- 7. The pharmaceutical composition according to claim 6 wherein the HMG-CoA reductase inhibitor is Atorvastatin.
- 8. The pharmaceutical composition comprising N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate, and a HMG-CoA reductase inhibitor.
- 9. The pharmaceutical composition according to claim 8 wherein the HMG-CoA reductase inhibitor is Pravastatin, Lovastatin, Simvastatin, Fluvastatin, Rivastatin, Atorvastatin, Rosuvastatin or Pitavastatin.
- 10. The pharmaceutical composition according to claim 8 wherein the HMG-CoA reductase inhibitor is Pravastatin, Lovastatin, Simvastatin, Fluvastatin,. Atorvastatin, Rosuvastatin or Pitavastatin.
- 11. The pharmaceutical composition according to claim 8 wherein the HMG-CoA reductase inhibitor is Pravastatin, Atorvastatin or Pitavastatin.
- 12. The pharmaceutical composition according to claim 8 wherein the HMG-CoA reductase inhibitor is Pravastatin or Atorvastatin.
- 13. The pharmaceutical composition according to claim 8 wherein the HMG-CoA reductase inhibitor is Pravastatin.
- 14. The pharmaceutical composition according to claim 8 wherein the HMG-CoA reductase inhibitor is Atorvastatin.
- 15. A method of prevention or treatment of atherosclerosis or xanthoma comprising administering to a human patient in need thereof, an effective amount of a combination of agents comprising N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or a pharmacologically acceptable salt thereof, and an HMG-CoA reductase inhibitor.
- 16. The method according to claim 15 wherein the HMG-CoA reductase inhibitor is Pravastatin, Lovastatin, Simvastatin, Fluvastatin, Rivastatin, Atorvastatin, Rosuvastatin or Pitavastatin.
- 17. The method according to claim 15 wherein the HMG-CoA reductase inhibitor is Pravastatin, Lovastatin, Simvastatin, Fluvastatin, Atorvastatin, Rosuvastatin or Pitavastatin.
- 18. The method according to claim 15 wherein the HMG-CoA reductase inhibitor is Pravastatin, Atorvastatin or Pitavastatin.
- 19. The method according to claim 15 wherein the HMG-CoA reductase inhibitor is Pravastatin or Atorvastatin.
- 20. The method of claim 15 wherein the HMG-CoA reductase inhibitor is Pravastatin.
- 21. The method according to claim 15 wherein the HMG-CoA reductase inhibitor is Atorvastatin.
- 22. A method of prevention or treatment of atheroscerlosis or xanthoma comprising administering to a human patient in need thereof, an effective amount of a combination of agents comprising N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate, and a HMG-CoA reductase inhibitor.
- 23. The method according to claim 22 wherein the HMG-CoA reductase inhibitor is Pravastatin, Lovastatin, Simvastatin, Fluvastatin, Rivastatin, Atorvastatin, Rosuvastatin or Pitavastatin.
- 24. The method according to claim 22 wherein the HMG-CoA reductase inhibitor is Pravastatin, Lovastatin, Simvastatin, Fluvastatin Atorvastatin, Rosuvastatin or Pitavastatin.
- 25. The method according to claim 22 wherein the HMG-CoA reductase inhibitor is Pravastatin, Atorvastatin or Pitavastatin.
- 26. The method according to claim 22 wherein the HMG-CoA reductase inhibitor is Pravastatin or Atorvastatin.
- 27. The method according to claim 22 wherein the HMG-CoA reductase inhibitor is Pravastatin.
- 28. The method according to claim 22 wherein the HMG-CoA reductase inhibitor is Atorvastatin.
Priority Claims (1)
Number |
Date |
Country |
Kind |
2000-265082 |
Sep 2000 |
JP |
|
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This is a Continuation Application of Ser. No. 09/943,712 filed Aug. 31, 2001, now pending, which claims priority under 35 USC 119(e) of U.S. Provisional Application Serial No. 60/230,601, filed Sep. 6, 2000, the entire disclosure of which is incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60230601 |
Sep 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09943712 |
Aug 2001 |
US |
Child |
10702930 |
Nov 2003 |
US |